Leap Therapeutics History

 Our History

First patient dosed with TRX518 001

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

First patient dosed with TRX518 001

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518

 
 

Team

Luke Andersen
Finance
Jay Baum, Ph.D.
Translational Medicine
Amy Belliveau
Manufacturing
Adam Connelly
Manufacturing
Alex V. De Windt, MD
Pharmacovigilance
Michael Haas, Ph.D.
 Research
Peter Hocknell, Ph.D.
Manufacturing
Michael Kagey, Ph.D.
 Research
Sri Kolluri_WebsitePic.JPG
Sri Kolluri
Clinical
Cliff Kwityn
Manufacturing
gus lawlor 2.PNG
Gus Lawlor
Chief Operating Officer
Matthew Lederhos
Finance
Kevin Lloyd
Program & Alliance Management
Jonathan Miller
Business Development
Diane Piper
Clinical
Chris Cropped.jpg
Chris Mirabelli, Ph.D.
Chairman of the Board
Capture walter.PNG
Walter Newman, Ph.D.
Senior Research Fellow
Mark.jpg
Mark O'Mahony
Chief Manufacturing Officer
Doug Onsi.jpg
Douglas Onsi
President & CEO
Lianna Sifferlen
Clinical
cyndi.jpg
Cyndi Sirard, M.D.
Chief Medical Officer
Robert Steinberg
Operations
Mathis Thoma
Clinical
Steve Tokatlyan
Operations

2006

First US patent filed for TRX518 

2009

First patient dosed with DKN-01 by Eli Lilly 

2010

First patient dosed with TRX518 at Memorial Sloan Kettering Cancer Center 

2010

First US patent granted covering sequence of DKN-01 

2016

Leap Therapeutics launched

2017

Leap Therapeutics becomes publicly listed on NASDAQ: LPTX 

2017

Initiated collaboration with Merck to evaluate DKN-01 in combination with Keytruda 

2018

Initiated collaboration with Pfizer/Merck KGaA to evaluate TRX518 in combination with Bavencio 

2020

Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01

2020

Leap Therapeutics Announces Orphan Drug Designation of DKN-01 for the Treatment of Gastric/Gastroesophageal Junction Cancer and Closes $45 million Public Offering of Common Stock

Board of Directors

Chris Mirabelli, Ph.D.
Chairman of the Board, Leap Therapeutics

Thomas Dietz, Ph.D.

Chairman and CEO of Waypoint Holdings

Doug Onsi, J.D.
President & CEO, Leap Therapeutics

Nissim Mashiach

Co-Founder of NuBiyota 

James Cavanaugh, Ph.D.
Managing Director at HealthCare Ventures

William Li, M.D.

CEO and President of Angiogenesis Foundation

Joseph Loscalzo, M.D., Ph.D, M.A.

Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital

Monica M. Bertagnolli, MD, FASCO

Chief, Division of Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center; Professor of Surgery, Harvard Medical School, Boston

 
 

Scientific Advisory Board

David Tuveson, M.D., Ph.D.
Chair of Leap SAB, Director of Research, the Lustgarten Foundation, Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory

Xi He, Ph.D.

Endowed Research Chair, Professor of Neurology, American Cancer Society Research Professor, Boston Children’s Hospital and Harvard Medical School
 

Eric P. Winer, M.D.

Senior Vice President and Chief Clinical Strategy Officer; Chief, Division of Women's Cancers, Dana Farber Cancer Institute; Director, Breast Oncology Program, Susan F. Smith Center for Women's Cancers; Thompson Chair in Breast Cancer Research Institute Physician; Professor of Medicine, Harvard Medical School
 

Carl F. Nathan, M.D.

Professor and Chairman of Department of Microbiology and Immunology at Weill Cornell Medical College
 

Andrew B Nixon, PhD, MBA

Professor of Medicine at Duke University Medical Center, Director of the Phase I Biomarker Laboratory and Associate Director of the Duke Center for Cancer Immunotherapy

Richard Gaynor, M.D.

President and Chief, Research and Development, at BioNTech US; Scientific Advisory Committee for Stand up to Cancer; Board of Directors of the Damon Runyon Cancer Research Foundation, Alkermes plc. and Infinity Therapeutics

Twiter Icon.png

© 2021 Leap Therapeutics, Inc.       All Rights Reserved